Syndax Pharmaceuticals (SNDX) Peer Comparison

$17.62

$0.02 (0.11%)

As on 05-Oct-2026 10:36EDT

Market cap

$1,572 Mln

Revenue (TTM)

$252 Mln

P/E Ratio

--

P/B Ratio

104.3

Div. Yield

0 %

Edit

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	1,572	16,732	14,995	14,468	12,469
Revenue ($ Mln)	252	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-220.77	491.50	755.85	860.62	413.60
Net Margin (%)	-87.60	17.67	71.69	35.33	24.86
RoE (%)	-553.79	110.09	--	42.98	430.03
Price to Earnings	--	35.22	17.89	18.36	31.39
Price-To-Book	104.32	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	252.00	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	6.37	1,982.07	103.47	85.67	363.07
Gross Profit	165.38	760.62	588.53	2,236.43	1,091.18
Operating Expenses	439.81	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-194.17	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-220.77	598.92	101.11	1,035.47	583.34
Provision for Tax	0.00	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-220.77	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	15.10	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	588.88	187.89	384.48	288.55	2,089.43
Current Liabilities	99.68	1,435.43	464.70	361.93	344.44
Total Liabilities	529.71	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	29.12	1,006.90	895.24	1,243.41	1,644.38
Current Assets	675.04	1,050.29	1,389.84	1,250.82	933.02
Total Assets	529.71	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	589.38	120.10	449.89	165.93	2,146.65
Net Current Assets	575.36	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-322.98	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	290.04	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	13.68	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-54.63	53.56	-30.01	32.82	15.61
ROE (%)	-553.79	110.09	163.18	42.98	430.03
ROA (%)	-29.19	15.64	31.68	29.32	16.19
EBIT Margin (%)	-53.67	21.13	5.73	41.23	36.28
Net Margin (%)	-87.60	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	-0.01	0.00	0.00	0.00	0.00

Growth Ratios

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	222.34	24.67	114.85	9.23	41.15
EBIT Growth (%)	59.91	18.70	136.39	27.56	-14.99
Net Profit Growth (%)	34.10	17.50	378.76	42.89	-25.78
EPS Growth (%)	35.13	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-90.69	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-6.38	36.06	-59.76	15.79	24.99
Price / Book Value	28.16	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-6.97	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	38.95	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.03	0.00	0.05	0.00	1.46
Current Ratio	6.77	0.73	2.99	3.46	2.71
Quick Ratio	6.44	0.73	2.32	3.38	2.31
Interest Coverage	-1.58	--	1.62	--	29.73

Operating Efficiency Ratios

	Syndax Pharmaceuticals (SNDX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	27.84	15.88	21.25	13.74	27.40
Asset Turnover	0.33	0.89	0.44	0.83	0.65
Receivable days	89.18	50.42	85.52	43.48	98.04
Inventory Days	867.80	--	1,056.70	96.17	190.34
Payable days	739.04	6.26	331.01	147.97	18.62
Cash Conversion Cycle	217.93	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly